הלוואות ואשראי לטווח ארוך של החברה: Larimar Pharma (LRMR)

Larimar Therapeutics (LRMR) is developing an innovative drug for Friedreich's ataxia backed by patent protection, while the development of its entire scientific foundation depends on FDA verdicts. This chart of current share prices captures the metric at 0.00. The absence of competitors in this niche provides the company with immense leverage over therapy costs and the ability to set premium pricing for insurance organizations.

Larimar Therapeutics (LRMR) operates in an emerging market for drugs treating rare neurological pathologies with high deferred demand. This indicator captures the aggregate of loans with maturities exceeding one year, determining long-term financial stability and the level of credit burden. By analyzing changes in the issuer's long-term liabilities, an investor assesses the company's ability to fund expansion without the risk of default. The stability of this metric confirms the business's fundamental readiness for a large-scale expansion of its patient base.